MentalHealthDaily

NLRP3 Inflammasome & Depression: A Target for Antidepressant Development?

by GLOOM

The NLRP3 inflammasome stands at the crossroads of immune response and mental health, playing a pivotal role in the inflammatory processes implicated in depression. Researchers are exploring the intricate relationship between NLRP3 activation and depressive disorders, highlighting the potential for innovative treatments targeting this complex molecular pathway. Highlights: NLRP3 Inflammasome Activation: NLRP3, a component of …

Allopregnanolone Agonists for Depression: Brexanolone & Zuranolone in Focus (2023)

by GLOOM

Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …

Top 12 Antidepressant Nutrients & Foods for Depression Treatment

by GLOOM

Depression is a growing public health concern, but nutrition may offer a pathway for prevention and treatment. A new research study identified the most nutrient-dense foods for brain health to inform dietary recommendations. Key Facts: 12 nutrients have evidence supporting a role in preventing and treating depression, including omega-3s, B vitamins, minerals like magnesium, and …

Dextromethorphan-Bupropion (Auvelity) for Depression: Clinical Trial Data for the New Rapid-Acting Antidepressant

by GLOOM

Major depressive disorder (MDD) is a significant global health concern, affecting over 280 million people worldwide. While numerous pharmacological options exist, challenges remain in achieving timely, robust, and sustained antidepressant response. Dextromethorphan-bupropion is a novel oral antidepressant recently approved by the FDA for MDD in adults that may address some of these unmet needs. Key …

D-Mannose & ACSS2 Enzyme: Rapid Depression Treatment via BDNF & TPH2

by GLOOM

Researchers have uncovered a critical role for the metabolic enzyme acetyl-CoA synthetase short-chain family member 2 (ACSS2) in depression, identifying it as a novel target for rapid-acting and long-lasting antidepressant therapies. Findings show ACSS2 regulates both brain-derived neurotrophic factor (BDNF) levels to improve synaptic plasticity and serotonin synthesis through tryptophan hydroxylase 2 (TPH2) to mediate …

Antidepressants (SSRIs) & Permanent Sexual Dysfunction (PSSD): A Risk to Consider

by GLOOM

Treatment with commonly prescribed antidepressants may cause a small proportion of patients to develop persistent sexual side effects that continue even after stopping the medication. This condition is known as post-SSRI sexual dysfunction (PSSD). Key Facts: The study found 0.46% of patients developed erectile dysfunction that continued after stopping antidepressants. This suggests the risk of …

Adjunct Celecoxib for Depression & Mania: Treatment with a COX-2 Inhibitor

by GLOOM

Celecoxib, a selective COX-2 inhibitor, shows promise as an effective and safe adjunct treatment for major depression and mania, according to a new comprehensive systematic review. The analysis also found celecoxib improved symptoms when used as a standalone antidepressant in patients with somatic disorders. However, evidence for efficacy in bipolar depression remains unclear. Key Facts: …